drugset
drugset / Trial / NCT03887442

Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy

NCT03887442 ↗

Phase 2 Terminated 17 enrolled Spanish Head And Neck Cancer Cooperative Group Merck Sharp & Dohme LLC · collabPivotal S.L. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) after progression to first line EXTREME-type treatment in patients undergoing maintenance treatment with cetuximab.

Timeline

Start
2011-02-16
Primary completion
2012-10-02
Completion
2012-10-02

Outcome

Outcome not reported

Stopped (Enrollment): “low recruitment rate”

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 250 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 80 mg/m2 Intravenous

Indications

head and neck squamous cell carcinoma